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ABSTRACT
A retrospective population-based study of genotypes of methicillin-resistant Staphylococcus aureus
(MRSA) was performed during the period 1991–2003 in two counties in the south-eastern part of
Norway. Isolates of MRSA from all individuals in the two counties in whom MRSA was detected were
genotyped by means of multilocus sequence typing (MLST), staphylococcal cassette chromosome mec
(SCCmec) typing, staphylococcal protein A gene (spa) typing and ampliﬁed fragment length poly-
morphism (AFLP) analysis. Until 1999, only sporadic cases of MRSA infection were reported in these
counties, but the incidence increased during the following years. Nine new MLST types were identiﬁed
in this study. The predominant strains were ST239-MRSA-III, the novel ST125-MRSA-IV, and the central
European community-acquired strain ST80-MRSA-IV reported previously. ST80-MRSA-IV was intro-
duced into the two counties in 1997, and the incidence of infections has increased since 2000, so that
ST80-MRSA-IV is now the commonest MRSA strain in the region. An increase in MRSA clones carrying
SCCmecIV has occurred during recent years, which could indicate a shift in the MRSA population in
Norway from hospital-acquired MRSA to community-acquired-MRSA.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA)
ﬁrst appeared during the early 1960s [1], and
today represents a signiﬁcant threat to public
health in most European countries.
The spread of MRSA in England and Wales
during the 1990s is interesting with regard to
public health interventions. The proportion of
cases of S. aureus bacteraemia caused by MRSA
increased from 1–2% in 1990–1992 to > 40% in
2000, with the emergence of two epidemic MRSA
(EMRSA) strains, EMRSA-15 and EMRSA-16,
coinciding with this increase [2–6], and the num-
bers of MRSA infections are still increasing [7,8].
In Norway, the proportion of MRSA involvement
in cases of bacteraemia caused by S. aureus has
remained at c. 1% [9]. The reasons for this low
percentage could be that Norway has a small
population spread over a relatively large area,
and that the country is situated geographically on
the periphery of Europe. For > 10 years, Norway
has had MRSA screening programmes for pa-
tients admitted to hospitals, and for healthcare
workers who have worked in hospitals outside
the Nordic countries. To obtain more information
concerning the dynamics of the spread of MRSA,
it would be interesting to examine the times at
which the different epidemic clones of MRSA
appeared in Norway, with particular emphasis on
the new community-acquired MRSA clones that
have been reported on the European continent.
The introduction of molecular typing tech-
niques for epidemiological investigations has
provided powerful new tools for tracking the
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origin and routes of dissemination of MRSA.
Several methods have been applied to genotype
MRSA isolates. However, most such methods
depend on comparing DNA fragment patterns,
which can lead to difﬁculties when comparing
results from different laboratories. However,
multilocus sequence typing (MLST) and staphylo-
coccal protein A gene (spa) typing are sequence-
based methods that are highly discriminatory and
provide universal algorithms that enable easy
comparison of the results [10–13]. MLST is based
on determining the sequences of internal frag-
ments of seven housekeeping genes, with each
fragment being c. 450 bp in length [11]. Spa typing
is based on analysing the polymorphic X region of
the staphylococcal protein A gene, situated at the
3¢ end of the gene, which consists of a variable
number of 24-bp repeats [12].
The aim of the present population-based study
was to include isolates from all patients from
whom MRSA was isolated during the period
1991–2003. A deﬁned geographical area in Nor-
way with a relatively high population density,
excluding the capital Oslo, was chosen for the
study. The MRSA isolates from the patients were
genotyped and compared with internationally
recognised strains using MLST supplemented
with staphylococcal cassette chromosome mec
(SCCmec) typing [14–16] and spa typing. Ampli-
ﬁed fragment length polymorphism (AFLP) ana-
lysis [17,18] was also investigated in comparison
with MLST and spa typing, as AFLP is one of the
routine epidemiological typing methods in use at
Akershus University Hospital.
MATERIALS AND METHODS
Population, design and bacterial strains
The population of Akershus and Østfold comprises 723 020
inhabitants. These two neighbouring counties are situated in
the south-eastern part of Norway, near the Swedish border,
and surrounding the capital of Norway, Oslo. The investiga-
tion was performed as a retrospective population-based study.
All 100 individuals in the region from whom MRSA was
isolated between 1991 and 2003 were included, comprising
hospitalised patients and patients from the primary healthcare
system. All isolates were genotyped (see below). Only one
sequence type (ST) was isolated from 99 individuals; the
remaining individual yielded two STs (101 isolates in total).
The MRSA isolates were obtained from the three microbiolo-
gical laboratories in the region. All laboratories stored MRSA
isolates at ) 80C. The possibility of samples with MRSA being
sent to other laboratories in the region was considered to be
negligible.
Identiﬁcation of MRSA
All MRSA isolates were identiﬁed following incubation for
2 days on Mueller–Hinton agar containing NaCl 2% w ⁄v,
oxacillin 4 mg ⁄L and aztreonam 8 mg ⁄L. Colonies were also
tested for oxacillin susceptibility by Etest (AB Biodisk, Solna,
Sweden) before storing. Before being genotyped, the MRSA
isolates were retested by PCR for the presence of the mecA and
nuc genes [19,20]. PCR was performed in 25-lL volumes
containing 20 ng of chromosomal DNA, 5 pmol of each primer,
0.2 mM dNTPs (Invitrogen, Carlsbad, CA, USA), 0.5 U of
Platinum Taq DNA polymerase (Invitrogen), 2.5 lL of 10·
buffer and 3.5 mM MgCl2 (both supplied with Platinum Taq
DNApolymerase).Ampliﬁcationwasperformed in aGeneAmp
9700 thermal cycler (AppliedBiosystems, FosterCity,CA,USA),
with 2 min at 94C, 30 cycles of 1 min at 94C, 30 s at 56C and
1 min at 72C, and a ﬁnal extension step of 10 min at 72C. PCR
products were visualised following electrophoresis on agarose
1.5% w ⁄v gels and staining with ethidium bromide 0.5 mg ⁄L
using a Gel Doc2000 system (Bio-Rad, Hercules, CA, USA).
Chromosomal DNA isolation
Bacterial cells were resuspended in double-distilled H2O, to a
concentration of c. 3 · 108 CFU ⁄mL, and were incubated with
lysostaphin (Sigma-Aldrich, St Louis, MO, USA) 0.25 mg ⁄mL
at 37C for 2 h. Chromosomal DNA was then extracted using
the GenoM-48 Robotic Workstation and the MagAttract DNA
tissue protocol, as recommended by the manufacturer (Gen-
oVision, Oslo, Norway).
MLST was performed according to the protocol of Enright
et al. [10], with minor modiﬁcations in the PCR mastermix. The
following seven housekeeping genes were analysed: carba-
mate kinase (arcC), shikimate dehydrogenase (aroE), glycerol
kinase (glpF), guanylate kinase (gmk), phosphate acetyl trans-
ferase (pta), triosephosphate isomerase (tpi) and acetyl coen-
zyme A acetyltransferase (yqiL). PCRs were performed in a
ﬁnal volume of 25 lL containing 25 ng of chromosomal DNA,
0.025 lg of each primer (except for tpi_up and tpi_dn, where
0.25 lg was added), 0.2 mM dNTPs, 0.5 U of Platinum Taq
DNA polymerase, 2.5 lL of 10· buffer and 1.5 mMMgCl2. The
ampliﬁed products were puriﬁed using a GFX96 PCR Puriﬁ-
cation Kit (Amersham Biosciences, Chalfont St Giles, UK),
followed by sequencing with a Big Dye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems). Unincorporated dye
terminators were removed from the extension products by
isopropanol precipitation, and the sequences of both strands
were analysed using an ABI Prism 3100 DNA Genetic
Analyzer (Applied Biosystems). The sequencing primers were
the same as those used for the initial PCR ampliﬁcation. The
sequences were submitted to the MLST database (http://
www.mlst.net), where they were assigned allele and sequence
numbers.
SCCmec typing
SCCmec typing was performed using PCR to detect the
presence of the various ccr and mec complexes. The ccr
complexes were identiﬁed using primers b2, a2, a3 and a4
[14], and the mec complexes were identiﬁed using primers mI-
1, mI-2, mcR2 and mcR3 [15], Is-2, Is-5, mA2 and mA6 [16]. All
PCRs were performed in 25-lL reaction volumes containing
10 ng of chromosomal DNA, 5 pmol of each primer, 0.2 mM
dNTPs, 0.5 U of Platinum Taq DNA polymerase, 2.5 lL of 10·
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buffer and 1.5 mM MgCl2. Ampliﬁcation comprised 30 cycles
of 94C for 30 s, 59C (55C for primers mI-1 and mI-2) for 30 s
and 72C for 1 min, followed by a ﬁnal extension step of 72C
for 7 min. The ampliﬁed products were visualised as described
above.
Spa gene typing
Spa typing was performed by ampliﬁcation and sequencing of
the variable X region situated at the 3¢ end of the spa gene.
Primer 1 (ACAACGTAACGGCTTCATCC) and primer 2
(AGCAGTAGTGCCGTTTGCTT) were designed according to
published sequence data (GenBank accession no. J01786) [21].
PCR was in 25-lL volumes containing 25 ng of chromosomal
DNA, 5 pmol of each primer, 0.2 mM dNTPs, 0.1 U of
Hotmaster Taq DNA polymerase (Eppendorf, Hamburg, Ger-
many) and 2.5 lL of 10· buffer (supplied with the polym-
erase). Ampliﬁcation comprised 94C for 2 min, followed by 25
cycles of 94C for 30 s and 65C for 45 s, followed by a ﬁnal
extension at 65C for 7 min. The ampliﬁed products were
puriﬁed and sequenced as described for MLST. The sequen-
cing primers were the same as those used in the initial PCR.
The sequences were analysed using the Ridom StaphType
software (http://spaserver.ridom.de/) [22].
AFLP analysis
AFLP was performed following the AFLP Microbial Finger-
printing Protocol (Applied Biosystems), but with a modiﬁed
PCR mastermix. PCRs were performed in 10-lL reaction
volumes containing 2.5 ng of chromosomal DNA, 2 pmol of
EcoRI primer, 6 pmol of MseI primer (Applied Biosystems),
0.2 mM dNTPs, 1 U of Platinum Taq DNA polymerase, 1 lL of
10· buffer and 2 mM MgCl2. The primers used were ﬂuores-
cently-labelled EcoRI-A and EcoRI-AT, and unlabelled MseI-C
primers. The reaction mix was subjected to the selective
thermal cycling program only. Ampliﬁed product (0.5 lL) was
added to a loading buffer comprising 12 lL of HiDi forma-
mide and 0.5 lL of GeneScan-500 Rox size standard (Applied
Biosystems). The mix was denatured at 95C for 4 min and
quick-chilled on ice for 1 min, before being loaded and
analysed on an ABI Prism 3100 DNA Genetic Analyzer. The
resulting data were analysed using Fingerprinting II v3.0
software (Bio-Rad) and a dendogram was constructed using
Pearson’s correlation coefﬁcient and cluster analysis by the
unweighted pair-group method with average linkages
(UPGMA). Only fragments between 50 and 500 bp were
analysed.
Based-upon-related sequence types (BURST) analysis
The relationship among the different MLST genotypes was
analysed using the clustering algorithm BURST [23], which
identiﬁes the most likely ancestral genotype and its descend-
ing variants.
RESULTS
MRSA MLST and SCCmec types
During the period 1991–2003, MRSA was isola-
ted from 100 individuals, of whom one yielded
two different STs (ST5-I and ST239-III), resulting
in 101 bacterial isolates being included in this
study. Between 1991 and 1999, up to ﬁve
patients with MRSA were detected each year,
except during 1992, when none was detected,
but there was an increase in the number of
individuals with MRSA between 2000 and 2003
(Fig. 1).
MLST identiﬁed 26 STs among the 101 isolates
(Table 1). ST80 was the most abundant sequence
type, representing 27% of the isolates (Fig. 2). In
addition to SCCmec types I–IV, the class C2 mec
complex was detected. Sixty-seven (66%) isolates
carried SCCmecIV, with an increase from 37%
of isolates during 1991–1999 to 73% during
2000–2003 (Fig. 1). SCCmecIV was detected in
14 different STs. SCCmecI was carried by 8%
(n = 8) of the isolates and was detected in ﬁve
STs; type II was carried by 8% (n = 8) and was
detected in four STs; and type III was carried by
15% (n = 15) and was detected in two STs. The
class C2 mec complex was carried by 3% (n = 3) of
the isolates and was detected in three STs. For
ST5, three different SCCmec types were identiﬁed
(Table 1).
The isolates from 80 individuals could be
classiﬁed into STs reported previously (Table 1).
Nine new STs were discovered: ST108-IV
(n = 1), ST110-II (n = 1), ST111-I (n = 1), ST112-
I (n = 1), ST113-IV (n = 1), ST114-II (n = 1),
ST125-IV (n = 12), ST140-IV (n = 1) and ST338-
C2 (n = 1). All of the isolates were related
closely to STs reported previously, differing by
only one mutation in one gene locus. All the
STs to which they were related were also
detected in this study, except for ST140-IV.
The relationship between the newly identiﬁed
STs and the STs described previously is shown
in Table 2.
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Fig. 1. Total number of isolates of methicillin-resistant
Staphylococcus aureus (MRSA) and MRSA isolates harbour-
ing SCCmecIV during 1991–2003.
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Nine of the 12 individuals infected with ST125-
IV were part of an outbreak involving two
nurseries and a hospital in one of the counties.
The other three individuals with the same strain
could not be connected epidemiologically with
the outbreak.
Five of the seven recognised global epidemic
MRSA clones were represented in the patient
material. These were ST5-I (EMRSA-3), ST8-IV
(EMRSA-2), ST22-IV (EMRSA-15), ST239-III (EM-
RSA-4) and ST247-I (EMRSA-5). In addition, two
patients carried ST36-II (EMRSA-16). Of the glo-
bal EMRSA strains, ST239-III was most prevalent,
with 13 individuals having been infected or
colonised with this strain.
Twenty-seven individuals were colonised with
ST80-IV, representing an annual increase in the
number of individuals colonised with this strain
(Fig. 2). All of these individuals had skin or soft-
tissue infection, and the infection was probably
acquired in the community. There was no known
epidemiological relationship among these
patients.
MRSA spa types
Thirty-eight spa types were detected in this study.
Eight STs included two or more spa types, giving
an additional resolution to MLST and SCCmec
typing (Table 1). The spa types found within an ST
differed in terms of the number and order of
repeats. Four spa types were represented in two or
more STs (Table 1). The STs sharing the same spa
type were closely related, differing by only 1 bp,
and all except ST110 had the same SCCmec type
(Table 1).
BURST and AFLP analysis of MRSA
The STs identiﬁed in this study grouped into 12
clonal complexes (CCs) when compared with the
S. aureus database at the MLST website (Table 1).
The newly discovered STs grouped into ﬁve of
these CCs. The STs sharing the same spa type
grouped into the same CC (Table 1).
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Fig. 2. Total number of individuals colonised or infected
with ST80-IV in Akershus and Østfold during the period
1991–2003.
Table 1. Clonal complexes (CCs), sequence types (STs),
SCCmec types and spa types of methicillin-resistant Sta-
phylococcus aureus (MRSA) isolates from all individuals
who were registered as MRSA-infected or -colonised in
two counties in the south-eastern part of Norway during
1991–2003
CC ST
SCCmec
type
spa type
(no. of
isolates)
No. of
isolates
Year of
isolation
1 1 IV t175 1 2000
5 5 I t149 1b 2001
5 II t002 4 2001, 2002
5 IV t311 1 2003
111 I t041 1 2002
114 II t002 1 1994
125 IV t067 12 1999, 2000, 2003
228 I t041 (1) ⁄ t109 (1) 2 2001
8 8 IV t008 (4) ⁄ t121 (1) ⁄
t304 (1) ⁄ t967 (1) ⁄ t986 (1)
8 1995, 1999, 2002
2003
110 II t037 1 1999
112 I t051 1 2003
113 IV t064 1 2002
239 III t037 (8) ⁄ t956 (4) ⁄ND (1) 13b 1991, 1996, 1997,
2000, 2001, 2003
241 III t037 (1) ⁄ t958 (1) 2 1998, 1999
247 I t051 3 1993, 1994
12 12 IV t160 1 2002
22 22 IV t020 (1) ⁄ t032 (3) 4 2001, 2002
30 30 IV t019 (3) ⁄ t021 (2)
t486 (1) ⁄ t964 (1)
7 2001, 2003
36 II t018 2 2000, 2001
37 IV t582 1 1998
45 45 IV t015 1 2000
108 IV t230 1 1997
59 59 C2 t437 1 2002
338 C2 t437 1 2003
78 88 IV t186 1 2003
80 80 IV t044 27 1997, 2000, 2001,
2002, 2003
152a 152 C2 t355 1 2003
140a 140 IV t957 1 2001
aContains only two STs, so no predicted ancestor could be found.
bOne individual carried two MRSA isolates, of ST5-I and ST239-III, respectively.
The total number of isolates in this study is 101, while the total number of
individuals is 100
ND, not determined.
Table 2. New sequence types (STs) identiﬁed in this
study, showing their SCCmec and spa types, and closely
related STs
ST
MLST allelic
proﬁle
SCCmec
type
Spa
type
Related ST
(SCCmec type, spa type)a
108 10-14-8-6-10-61b-2 IV t230 45 (IV, t015)
110 2-3-1-38b-4-4-3 II t037 239 (III, t037)
111 1-4-1-4-46b-24–29 I t041 228 (I, t041)
112 3-3-1-12-4-4-55b I t051 247 (I, t051)
113 3-3-1-1-4-62b-3 IV t064 8 (IV, t008, t121, t304, t967)
114 41b-4-1-4-12-1-10 II t002 5 (II, t002)
125 1-4-1-4-12-1-54b IV t067 5 (IV, t311)
140 43-37-48-19-49-26-39 IV t957 601c
338 19-23-15-48b-19-20-15 C2 t437 59 (C2, t437)
aRelated ST with SCCmec and spa type, as found among other isolates in the present
study.
bNew allelic proﬁle number that differs from the related ST.
cST not detected in the present study, but found in the MLST database.
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AFLP analysis recognised all CCs, but did not
differentiate among the different STs in the
complexes (Fig. 3). The homologies of the differ-
ent CCs containing more than two isolates were:
79% for CC8; 81% for CC5; 84% for CC30; and
91% for both CC80 and CC22. STs from different
CCs did not cluster together.
DISCUSSION
This study demonstrated that epidemic MRSA
clones colonised individuals in Norway as early
as 1991 (ST239-III), and that ﬁve of the seven
global epidemic hospital strains (in addition to
EMRSA-16) have now colonised individuals in
the two Norwegian counties studied. MRSA
strains ST239-III and ST125-IV, and the commu-
nity-acquired (CA) MRSA strain ST80-IV, were
the most prevalent strains, representing c. 51.5%
of the isolates. These strains could represent the
beginning of endemic MRSA clones in the two
counties. Oliveira et al. [24] reported that ST239 is
among the most prevalent MRSA clones in Por-
tuguese hospitals, and the fact that the present
study detected ST239-III between 1991 and 2003
indicates that this strain is becoming endemic in
hospital environments in Norway. However, this
global EMRSA is also common in other countries,
such as China, Taiwan and the USA [25–27], and
its isolation could simply represent new importa-
tions to Norway. A new ST, ST110, differing from
ST239 by one point mutation in the gmk allele,
was detected in the present study. Both were spa
type t037, but as ST110 was SCCmecII while ST239
was type III, no direct evolutionary descent is
likely.
Twelve individuals were colonised or infected
with a newly deﬁned ST, termed ST125-IV, which
is closely related to ST5-IV (the ‘paediatric clone’),
differing by only 1 bp in the yqiL allele. ST125-IV
has also been isolated in northern Norway and in
a Spanish university hospital in Tenerife [28,29].
In the Spanish hospital, ST125-IV was ﬁrst isola-
ted in 2001, disseminated rapidly, and represen-
ted 22.8% of the isolates during 2002. In the
present study, ST125-IV appeared ﬁrst in 1999, in
an outbreak involving a hospital and two nurser-
ies. The outbreak was discovered by routine
AFLP genotyping and was resolved after infec-
tion control interventions in 2003. Nine of the
patients infected with this strain were part of this
outbreak. Another three individuals were found
to carry this strain, but could not be connected
epidemiologically with the outbreak. To our
knowledge, ST125-IV has not been detected else-
where; however, the t067 spa type found in the
ST125-IV isolates has also been reported in other
countries.
AFLP analysis grouped the MRSA isolates into
clusters according to the CCs, but did not dis-
criminate among the different STs or spa types
inside each CC. This could be a result of muta-
tions in variable regions of the chromosome being
detected by the chosen AFLP protocol, while the
more conservative single-locus variation in the
housekeeping genes was not affected. This phe-
nomenon is especially signiﬁcant in the CC5
group, where the new single-locus variant ST125
intermingles with the other STs within the main
cluster.
The increasing incidence of the CA-MRSA
strain ST80-IV gives reason for concern that this
strain is becoming endemic in the community.
ST80-IV is recognised as a toxigenic virulent
strain [30], and was ﬁrst reported at a university
hospital in Greece [31]. The origin of ST80 is not
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Fig. 3. Dendogram showing ampli-
ﬁed fragment length polymorphism
analysis of representative sequence
types (STs) from CC5 and CC8, the
two clonal complexes containing the
largest number of STs, and ST80,
which was the most abundant ST in
this study.
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known, but a search of the MLST database
revealed four clones differing by a single-locus
variant from ST80, namely ST153 from Denmark,
ST397 and ST602 from The Netherlands, and
ST635 from Algeria, which might result from the
evolution of ST80. A study of CA-MRSA in
northern Norway showed an increase in the
isolation of ST80-IV during recent years [29]. It
is not known why this strain is disseminating so
rapidly in both the northern and the south-eastern
parts of Norway.
Hanssen et al. [29] reported two predominant
clones and several sporadic cases of MRSA
in northern Norway. This agrees with the present
ﬁndings, with 23 STs represented by eight or
fewer isolates, and three predominant STs. As in
northern Norway, SCCmecIV predominated,
accounting for 66% of the isolates. SCCmecIV is
small in size compared with types I, II and III, and
does not harbour genes coding for resistance to
non-b-lactam antibiotics. These are properties that
might result in SCCmecIV being transmitted more
easily from one S. aureus strain to another com-
pared with other SCCmec types. SCCmecIV is
predominant among CA-MRSA strains and is
found rarely in hospital-acquired MRSA strains
[16,32]. SCCmecIV may offer a better ability to
survive in the community, where high growth
rate and colonisation ability are more advanta-
geous than having multiple antibiotic resistance
genes [33].
If SCCmecIV is an indicator of CA-MRSA, the
majority of isolates in the present study were
community-acquired. The number of type IV
isolates increased from 37% of the total MRSA
isolates in 1991–1999 to 73% in the period 2000–
2003. Type IV was represented by 14 STs, while
the other types were represented by ﬁve or fewer
STs. This supports earlier ﬁndings that CA-MRSA
strains have a high clonal diversity [16,32]. In
addition to SCCmecIV, three isolates of different
STs were found to carry the class C2 mec complex,
a complex reported to be carried by CA-MRSA
[16]. The ﬁrst isolate of this type appeared in 2002,
and the other two isolates during 2003. In the
present study, 37 of the 40 MRSA isolates from
2003 carried the SCCmecIV or class C2 mec
complex. This could represent a shift in the
MRSA population in Norway to CA-MRSA.
As well as ﬁnding new STs, the present study
also detected the related STs, with the exception
of ST140-IV. It is noteworthy that the SCCmec
types for both new and related STs were identical,
with the exception of ST110. The spa types for ﬁve
of the new STs were identical to the spa type of the
related STs. These new STs may represent the
evolution of MRSA clones in Norway, or could
have originated in other geographical areas and
been imported to Norway. Reports from the
Norwegian National Institute of Public Health
indicate that 59% (72 of 122) of individuals with
reported MRSA infection in Norway during 2001
acquired the infection in Norway. By 2003, this
number had increased to 69% (149 of 216) [9],
which is in agreement with the present ﬁndings.
The development of new STs in Norway, and
especially the increase in such development in the
second half of the period, is consistent with the
trend indicated by the national surveillance pro-
gramme of an increased number of individuals
being infected in Norway. However, the national
surveillance programme gives no information
concerning predominant strains.
In conclusion, this study demonstrates that
global epidemic hospital-acquired MRSA strains
were present in Norway during the period 1991–
2003. Infections with the European community-
acquired strain ST80-IV were detected as early as
1997, with an increasing incidence during 2000–
2003. This strainwill probably establish itself in the
Norwegian community in the absence of appro-
priate public health interventions. There are also
indications of increased rates of evolution of new
MRSA clones in Norway. The increase in MRSA
clones harbouring SCCmecIV during recent years
could indicate a shift in theMRSApopulation from
hospital-acquired to community-acquired strains.
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